Standard clone selection focused solely on titer often overlooks purification hurdles like aggregation, fragmentation, and instability, which can delay scale-up.
By integrating early high-throughput analytics, advanced gene integration, and host-cell engineering, development teams can resolve critical quality constraints before final selection. Unifying CLD, upstream, and downstream workflows minimizes technical handoff risks and establishes a robust foundation for seamless technology transfer.
Read our full article in the European Pharmaceutical Review to explore these integrated CLD methodologies (Pages 66-67).
Standard clone selection focused solely on titer often overlooks purification hurdles like aggregation, fragmentation, and instability, which can delay scale-up.
By integrating early high-throughput analytics, advanced gene integration, and host-cell engineering, development teams can resolve critical quality constraints before final selection. Unifying CLD, upstream, and downstream workflows minimizes technical handoff risks and establishes a robust foundation for seamless technology transfer.
Read our full article in the European Pharmaceutical Review to explore these integrated CLD methodologies (Pages 66-67).
Share article
Related Content